The Organic Chemistry of Drug Design and Drug

advertisement

The Organic Chemistry of

Drug Design and Drug

Action

Chapter 8

Drug Metabolism

Drug Metabolism

Foreign organism – elicits antibody response

Low molecular weight xenobiotics – nonspecific enzymes convert them into polar molecules for excretion

Enzymatic biotransformations of drugs – drug metabolism

Principal site of drug metabolism is the liver; also kidneys, lungs, GI tract take via mouth

Pathway of Oral Drugs absorbed through small intestine or stomach bloodstream liver

(first metabolized)

Drug metabolism by liver enzymes – first-pass effect

Avoid first-pass effect by changing the route of administration

• sublingual route (under the tongue) bypasses liver

- angina (sublingual)

• rectal route (suppository or enema)

- migraine headaches (rectal)

• intravenous (i.v.) injection – rapid response, circulation time of 15 seconds

Avoid first-pass effect by changing the route of administration (cont’d)

• intramuscular (i.m.) injection – for large volumes or slow absorption

• subcutaneous (s.c.) injection – through loose connective tissue of s.c. layer of skin

• pulmonary absorption – gaseous or highly volatile drugs

- asthma (aerosol)

• topical application

Prodrug approaches are discussed in Chapter 9

Drug metabolism is desirable once drug has reached site of action – may produce its effect longer than desired or become toxic.

Drug metabolism studies are essential for the safety of drugs. Metabolites must be isolated and shown to be nontoxic.

An active metabolite that is less toxic

• Terfenadine is cardiotoxic, since it binds to the hERG channel

• Fexofenadine has similar antihistamine activity, but no hERG activity

Synthesis of Radioactive Compounds

To increase sensitivity for detection of metabolites, radioactivity is incorporated into the drug candidate.

Incorporate a commercial radioactive compound near the end of the synthesis, if possible.

Usually the radioactive synthesis is different from that of the unlabeled compound.

[ 14 C] preferable to [ 3 H] – 3 H has shorter t

1/2 cleavage; loss of 3 H as 3 H

2

; isotope effect on C-H

O if C-H cleavage occurs

Only a trace amount of radioactivity is used (maybe 1 in 10 6 molecules); the remainder of the molecules is nonradiolabeled.

Metabolism of erythromycin

If the NMe

2 group is labeled with the [ 14 C]-CO

2 can be measured.

14 C,

If the drug is a natural product, a biosynthetic approach to radioactive incorporation is best

SCHEME 8.1

Biosynthesis of penicillins

If the drug is not a natural product, a chemical synthesis is needed.

[ 14 C] acetic anhydride could be used here

SCHEME 8.2

Chemical synthesis of linezolid

The radioactive drug is used in metabolism and bioavailability studies in rats, mice, or guinea pigs, then in dogs and/or monkeys.

If >95% of the radioactivity is found in urine and feces, and is nontoxic, it can be administered to humans.

Phase I clinical trials on healthy volunteers – radiolabeled drug administered to humans for human metabolism studies.

Advances that Made

Metabolism Studies Less

Difficult

More commercially-available radioactive compounds

High performance liquid chromatography (HPLC); new column packings; capillary GC; capillary electrophoresis

New mass spectrometric methods – tandem mass spectrometry/mass spectrometry; GC/mass spectrometry;

*HPLC/electrospray mass spectrometry

New nuclear magnetic resonance (NMR) techniques

*HPLC/NMR

*HPLC/NMR/MS

Principal Steps in Drug Metabolism

Studies

1.Isolation (often, this step can be omitted) – extractions, ion exchange

2.Separations – HPLC, GC

3.Identification – mass spectrometry (MS), NMR

4.Quantification – radioactive labeling, GC, HPLC

LC/MS/MS is a rapid method in which a sample is injected into the HPLC, then each peak is run into an electrospray ionization MS for parent ion data, then the parent ion is run into a second MS for fragmentation data.

Pathways for Drug Deactivation and

Elimination

• Rate and pathway of drug metabolism are affected by species, strain, sex, age, hormones, pregnancy, and liver diseases.

• Drug metabolism is stereoselective, if not stereospecific.

• Generally, enantiomers act as two different xenobiotics – different metabolites and pharmacokinetics.

• Sometimes the inactive enantiomer produces toxic metabolites or may inhibit metabolism of active isomer.

• Metabolism of enantiomers may depend on the route of administration.

• For example, the antiarrhythmia drug verapamil is 16 times more potent when administered i.v. than orally.

As the lipophilicity increases, metabolism increases; increased lipophilicity leads to better substrate activity with metabolizing enzymes.

FIGURE 8.1

Effects of lipophilicity on direct renal clearance and on metabolism

Verapamil is 16 times more active IV than orally

The more active (-) isomer is metabolized faster than the (+) isomer by the liver

(Advil)

Inactive ( R )-isomer is metabolized to active ( S )-isomer

No need to use a single enantiomer

One enantiomer can be metabolized to the other.

Drug metabolism reactions – two categories

Phase I transformations – introduce or unmask a functional group, e.g., by oxygenation or hydrolysis

Phase II transformations – generate highly polar derivatives (called conjugates) for excretion

Phase I Transformations

Oxidative Reactions

Late 1940s, early 1950s

Metabolism of 4-dimethylaminoazobenzene shown to require O

2 and a reducing system (NADPH).

Called a mixed function oxidase.

One atom of O from O

2 is incorporated into product; a heme protein is involved.

Cytochrome P450 – family of heme enzymes that catalyzes the same reaction on different substrates

(isozymes)

Drug-Drug Interactions

Changes in the pharmacokinetics and metabolism of drugs when multiple drugs are taken together.

One drug may inhibit a cytochrome P450, blocking metabolism of another drug.

One drug may induce a cytochrome P450, which increases metabolism of other drugs.

Hyperforin is found in St.

John’s Wort

Active constituent of St. John’s wort (hyperforin, 8.11

) activates the pregnane X receptor, which regulates P450 3A4 transcription, resulting in more active drug metabolism

Heme-dependent Mixed Function Oxidase

Scheme 4.35

Oxidizing agent

Reducing agent

Activated coenzyme

Reactions Catalyzed by Cytochrome P450

Site of Reactions Catalyzed by P450

Part of molecule undergoing reaction is determined by:

1. topography of the active site of the isozyme

2. degree of steric hindrance of the heme iron-oxo species to the site of reaction

3. ease of H atom abstraction or electron transfer from the compound

CYP450 activity is variable in the population

CYP450 is found in liver, kidney and lungs.

There are a number of different P450 families, which differ in their substrate and reaction specificity.

57 human genes for P450 have been indentified.

Individuals also vary in the properties of their P450s.

CYP450 2C9 and 2D6 are responsible for metabolism of about half of all drugs.

Variations in P450s are racially and ethnically distributed.

Pharmacogenomics—how the genetic characteristics of a person influences their response to drugs.

Individual variation in CYP450 2C9

CYP450 2C9 metabolizes phenytoin, S-warfarin, tolbutamide, losartan, and many nonsteroidal antiinflammatory agents

(NSAIDs).

At least 33 alleles of CYP450 2C9 have been discovered.

Most of the mutant alleles of CYP450 2C9 have low or no enzymatic activity.

CYP450 2C9 and tolbutamide metabolism

• Tolbutamide is a sulfonylurea antidiabetes drug.

CYP450 2D9 hydroxylates the aromatic methyl to give a much lower activity metabolite.

Individuals with mutant CYP450 2C9 alleles have higher concentrations of tolbutamide in the blood, longer duration of action, and lower blood glucose, so they are more likely to get hypoglycemia.

CYP450 2C9 and warfarin metabolism

Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase.

(S)-Warfarin is hydroxylated at C-6 and C-7 by

CYP450 2C9 to give inactive metabolites.

Mutant alleles of CYP450 2C9 have less activity for hydroxylation of warfarin, so patients with mutant alleles need to have lower doses.

The therapeutic index for warfarin is small even for wild-type patients.

Individual variation in CYP450 2D6

P450 2D6 metabolizes opiates, antiarrhytmics, tamoxifen and b

-blockers, among others.

More than 60 alleles of 2D6 have been discovered.

Some of the alleles of 2D6 have low or no enzymatic activity (PM).

Some of the alleles of 2D6 have intermediate activity

(IM).

Some of the alleles of 2D6 have somewhat higher activity (EM).

Some of the alleles of 2D6 have much higher activity than wild-type (UM).

CYP450 2D6 and opiate metabolism

Codeine is O-demethylated to morphine, the active metabolite in analgesia.

PMs can’t convert codeine to morphine, so don’t get analgesia.

UMs convert codeine to morphine very rapidly, so may experience toxicity .

Infants have been poisoned by breast milk from UM mothers taking codeine

.

CYP450 2D6 and tamoxifen metabolism

• Tamixofen is an antiestrogen used to treat breast cancer.

The metabolite, 4-hydroxytamoxifen, binds about 100-fold more strongly to estrogen receptors.

2D6 PMs respond poorly to tamoxifen treatment.

Reactions of Flavin

Monooxygenase

Table 8.2

Flavin monooxygenase is often more stereoselective than CyP450

CyP450 CyP450

FMO

Flavin Monooxygenase

(another mixed function oxidase)

Scheme 4.34

Nucleophiles with anionic groups are not substrates

X is N or S

Aromatic Hydroxylation

Intermediate in aromatic hydroxylation

Jerina, Daly and Witkop

1968 National Institutes of Health (NIH) arene oxide isolated

SCHEME 8.3

Cytochrome P450 oxidation of naphthalene

Mechanism for Arene Oxide Formation and

Aromatic Hydroxylation

(favored over a)

SCHEME 8.4

Addition

–rearrangement mechanism for arene oxide formation

Reactions of

Arene Oxides

SCHEME 8.5

Possible fates of arene oxides toxic effects

Rearrangement of Arene Oxide to Arenol

Called the

NIH shift

SCHEME 8.6

Rearrangement of arene oxides to arenols (NIH shift)

Competing with the NIH Shift

deprotonation

The more stabilized the carbocation intermediate, the less favored for hydride shift - more deprotonation.

SCHEME 8.7

Competing pathway for NIH shift

Deuteration can reduce metabolism

Deuterated linezolid has t

1/2

6.3 h, compared to 4.5 h

=

NIH Shift with Groups Other than H

p -chloroamphetamine

Oxidation of a halogen-substituted aromatic ring is quite rare.

SCHEME 8.8

NIH shift of chloride ion

A common approach to slow down or block aromatic hydroxylation is to substitute the phenyl ring with a para -fluorine or para -chlorine

(deactivates the ring).

The half-life for the anti-inflammatory drug diclofenac ( 8.22

) is 1 h; for fenclofenac ( 8.23

) is

>20 h.

NIH Shift of a Nitro Group

Scheme 8.9

antiprotozoal

This reaction is electrophilic aromatic substitution

Favors electron-donating substituents

No aromatic hydroxylation if strongly electron-withdrawing substituents e withdrawing uricosuric agent

For drugs with 2 aromatic rings, the more e -rich one usually is hydroxylated.

hydroxylation here e withdrawing

- antipsychotic

Species Specificity

Major hydroxylation metabolites in dogs pro-R

Maybe a different isozyme pro-S in humans

- antiepilepsy

Mechanism of Epoxide Hydrolase

Hydration of Arene Oxide trans -diol anti attack

SCHEME 8.10

Metabolic formation and oxidation of catechols

Glutathione S-transferase Reaction with Arene Oxide

SCHEME 8.11

Formation of glutathione adducts from naphthalene oxides

Toxicity from Arene Oxides

SCHEME 8.12

Deoxyribonucleic acid adduct with benzo[a]pyrene metabolite benzo[a]pyrene alkylation of

DNA and RNA

Relationship between soot and cancer noted in 1775 chimney sweeps frequently developed skin cancer

Alkene Epoxidation

Also an anticonvulsant anticonvulsant

SCHEME 8.13

Metabolism of carbamazepine

Toxic Product of Alkene Oxygenation aflatoxin B

1

DNA adduct

SCHEME 8.14

Metabolic reactions of aflatoxin B

1

Oxidation of Carbons Adjacent to sp 2

Centers

Oxygenation next to aromatic sp 2 carbon antidepressant

Hydroxylation stereochemistry at C -1  depends on stereochemistry at C -2 in metoprolol.

antihypertensive

Stereochemistry at C -2 will affect how the molecule binds in P450, which determines which H is closest to the heme iron-oxo species.

Allylic Hydroxylation antiarrhythmic

Oxidation gives 7.38

(R = OH)

Allylic hydroxylation of THC

Oxidation Next to a Carbonyl Group

Enantiomer difference in metabolism hydroxylation here for (+)-isomer hydroxylation here for (-)-isomer sedative/hypnotic

Oxidation at Aliphatic and Alicyclic

Carbons

Both positions are hydroxylated anticonvulsant

Perhexiline is hydroxylated

Hydroxylation beta to a Carbonyl Group

SCHEME 8.15

C -demethylation of a flutamide metabolite

Oxidations of Carbon-Nitrogen Systems

Oxidative Deamination

Cleavage of NH

3 from 1° amines

SCHEME 8.16

Oxidative deamination of primary amines

Oxidative Deamination of amphetamine

N-Oxidation-Hydroxylation of Nitrogen

SCHEME 8.17

N -Oxidation pathways of amphetamine

Basic amines (p K a

8-11) are oxidized by flavoenzymes. Nonbasic compounds, such as amides, are oxidized by P450. Compounds of intermediate basicity, such as aromatic amides, are oxidized by both.

Alternative Pathway to Ketone

SCHEME 8.18

Amphetamine imine formation via the carbinolamine

Metabolism of 2° Amines and Amides

Oxidative N-Dealkylation

SCHEME 8.19

Oxidative N -dealkylation of secondary amines

Oxidation here a b

Oxidation here

SCHEME 8.20

Oxidative metabolism of propranolol

N-Oxidation of 2

Amines

anorectic

SCHEME 8.21

N -Oxidation of fenfluramine

Further oxidation occurs

Oxidation of 3° Amines and Amides

No oxidative deamination

Oxidative N-Dealkylation

Rate of oxidative N -dealkylation of 3  amines > oxidative N -dealkylation of 2  amines > oxidative deamination of 1  amines antihypertensive drug antidepressant drug

Rate of metabolism

R = NMe

2

> NHMe > NH

2

Enantioselective Oxidative N-Dealkylation

N -Demethylation of (+)-isomer is slower than that of (-)-isomer narcotic analgesic

SCHEME 8.22

Metabolism of selegiline (deprenyl)

( S )-(+)-deprenyl  ( S )-(+)-methamphetamine  ( S )-(+)-amphetamine weak MAO B inhibitor undesirable CNS stimulant

( R )-(-)-deprenyl  ( R )-(-)-methamphetamine  ( R )-(-)-amphetamine potent MAO B inhibitor weak CNS stimulant

Therefore only the ( R )-(-)-isomer is used

Rasagiline avoids the stimulation problem with Seligiline

Alicyclic 3°

Amine Oxidation

SCHEME 8.23

Oxidative metabolism of nicotine leading to C –N bond cleavage

.

Evidence for Iminium Ion Intermediates local anesthetic

SCHEME 8.24

Metabolism of lidocaine isolated

N-Oxidation of 3° Amines

N -Oxidation antihypertensive

Cyproheptadine forms the Noxide in dogs

N

-Oxidation of 3° Aromatic Amines

Two enzymes systems: P450 and flavin monooxygenase

P450 catalyzed N -oxidation

SCHEME 8.25

Mechanism of cytochrome P450-catalyzed N -oxidation of tertiary aromatic amines

N -Oxidation by P450 occurs only if there are no  -hydrogens available or if the iminium radical is stabilized by electron donation.

Flavin Monooxygenase-Catalyzed

N-Oxidation of Aromatic Amines

SCHEME 8.26

Possible mechanism for N -oxidation of primary arylamines

Primary aromatic amines are generally not substrates for flavin monooxygenase; 2  and 3  aromatic amines are good substrates.

Two Pathways for N-Demethylation of

3  Aromatic Amines

SCHEME 8.27

Two pathways to N -demethylation of tertiary aromatic amines

Evidence to Support Carbinolamine

Formation

R = OH isolated

Mechanism of Carbinolamine

Formation

Based on low intrinsic isotope effects by P450, direct

H  abstraction mechanism was excluded.

SCHEME 8.28

Mechanism of carbinolamine formation during oxidation of tertiary aromatic amines

N-Oxidation of Aromatic Amines (1  and 2  )

Generation of reactive electrophiles acetylation or sulfation

SCHEME 8.29

Metabolic activation of primary and secondary aromatic amines

Cytotoxicity of N-Hydroxylated Amides

Mechanism-based inactivator if 8.78

does not escape the enzyme prior to nucleophilic attack

SCHEME 8.30

Arylhydroxamic acid

N,O -acyltransferase-catalyzed activation of N -hydroxy-2-acetylaminoarenes

Amide N-Demethylation sedative

N-Oxidation of 1  and 2  Aromatic Amides

Generation of electrophiles

2-acetylaminofluorene

(R = H) carcinogenic agent

Toxicity of Acetaminophen

Two possible mechanisms for generation of reactive electrophile 8.80

SCHEME 8.31

Initial proposals for bioactivation of acetaminophen

Another possible mechanism for

Acetaminophen Hepatotoxicity

SCHEME 8.32

Bioactivation of acetaminophen via a radical intermediate

Ethanol induces a P450 isozyme that generates the radical; alcoholics have a higher incidence of acetaminophen hepatotoxicity.

Acetaminophen also causes renal damage, but little P450 is in the kidneys.

Prostaglandin H synthase is in high concentrations in kidneys.

Prostaglandin H synthase contains heme just like

P450 and catalyzes similar reactions

SCHEME 8.33

Proposed bioactivation of acetaminophen by prostaglandin H synthase

Oxidations of Carbon-Oxygen Systems

Oxidative O-Dealkylation

Same mechanism as oxidative N -dealkylation

O -Demethylation is rapid; as increase alkyl chain length, O -dealkylation gets faster up to propoxyl, then rate decreases.

Cyclopropyl gives ethers with longer plasma half lives.

Indomethacin is demethylated

Oxidative O-Dealkylation of codeine analgesic

O -Demethylation by Cyp450 2D6 is rapid

Regioselective O-Demethylation

In dogs O -demethylation only here blood pressure maintenance

Oxidation on the Carbon Next to a

Lactone Oxygen

SCHEME 8.34

Metabolic hydroxylation of rofecoxib

Oxidations of Carbon-Sulfur Systems

Three principal biotransformations: Oxidative

S -dealkylation, desulfuration, and S -oxidation

Oxidative S -dealkylation

Dealkylation occurs here sedative

Desulfuration (C=S  C=O) anesthetic sedative

S-Oxidation

SCHEME 8.35

Cytochrome P450-catalyzed oxidation of sulfides

Occurs with P450 and flavin monooxygenase

Flavin monooxygenase gives sulfoxides only

P450 gives both S -dealkylation and sulfoxides

antihelmintic agent

Gives both S -dealkylation and S -oxidation metabolites

Thioridazine is oxidized on both sulfurs

Thiophenes are converted to thiophene S -oxides, which are electrophilic and can bind to liver proteins.

added in vitro to mimic a liver protein cysteine residue

SCHEME 8.36

S -Oxidation of tienilic acid

Oxidation of Sulfoxide to Sulfone

Oxisuran, an immunosupressive drug, is oxidized to the sulfone

Other Oxidative Reactions

Oxidative Dehalogenation volatile anesthetic

SCHEME 8.37

Oxidative dehalogenation of halothane

Oxidative Aromatization

Oxidation products of morphine

Oxidation of Alcohols to Aldehydes and

Aldehydes to Carboxylic Acids

Scheme 8.38

al coh ol d ehydr ogen ase

RCH

2

OH + NAD + RCHO + NADH + H + al dehyde dehydr oge nas e RCHO + NAD + + H

2

O RCOOH + NADH + H +

Oxidation of an aldehyde to a carboxylic acid is generally faster than reduction of an aldehyde to an alcohol.

Cytochrome P450 also oxidizes alcohols to aldehydes and aldehydes to carboxylic acids.

Oxidation of an Alcohol to a Carboxylic

Acid by NAD + Enzymes anti-AIDS drug

Oxidation of an Alcohol to a Carboxylic

Acid by a P450 Isozyme antihypertensive drug

The metabolite is 10 times more potent an antagonist of the angiotensin II receptor than losartan.

Reductive Reactions

Carbonyl Reduction

Typically aldo-keto reductases that require NADPH or NADH

Reduced here

Hydroxylated here

(R)-isomer:

(R,S) alcohol

(S)-isomer:

R=OH +

4:1 (S,S) : (S,R) alcohols

When the racemic mixture was administered, the R -isomer gave aromatic hydroxylation (both 6and 7-hydroxyl) as the major metabolites. Administration of racemates can affect the metabolism of each enantiomer.

Species Variation in Stereochemistry opioid antagonist used for addiction rehabilitation

6  -alcohol ( 7.102

, R 1 = OH, R 2 =

H) in chickens

6 b -alcohol ( 7.102

, R 1 = H, R 2 =

OH) in rabbits and humans

 , b -Unsaturated Ketone Double Bonds

Reduced

7.94

, R 3 = Et) and norethindrone ( 7.94

, R 3 = Me) is reduced; norgestrel gives 3  -alcohol (R 1 = H, R 2 = OH) but norethindrone gives 3 b -alcohol (R 1 = OH,

R 2 = H).

Double bond reduced

Nitro Reduction

SCHEME 8.39

Nitro group reduction

Nitro Reduction

Often the amine metabolite is not observed because it is easily air oxidized back to the nitro compound, for example, the anti-parasitic agent niridazole is reduced to the hydroxylamine, but is reoxidized to niridazole, and clonazepam is reduced to the unstable amine.

Nitro reduction with ring opening

SCHEME 8.40

Reductive metabolism of nitrofurazone

Azo Reduction

SCHEME 8.41

Azo group reduction

Azo Reduction

SCHEME 8.42

Reductive metabolism of sulfasalazine

Reduction carried out by intestinal bacteria.

Reduction of Azido to Amino

Anti-AIDS

3

Amine Oxide Reduction

imipramine N -oxide

Reduced in the presence of O

2 to the amine

Reductive Dehalogenation

SCHEME 8.43

Reductive dehalogenation of halothane

Cytochrome P450 in the absence of O

2

May be the cause for

Halothane hepatitis

Carboxylation Reactions

Metabolized to 8.124

, R = COOH

Hydrolytic Reactions

(nonspecific esterases and amidases in plasma, liver, kidney, and intestines)

Electron-withdrawing groups accelerate hydrolysis.

Conjugation with carbonyls decelerates hydrolysis.

Steric hindrance decelerates hydrolysis.

Hydrolyzed by all human tissues

Selectivity for Aliphatic vs.

Aromatic Esters

Some esterases catalyze the hydrolysis of aliphatic esters and others aromatic esters.

In vivo hydrolysis

Hydrolysis by liver enzymes in vitro

Amide vs. Ester Hydrolysis

Generally amides are more slowly hydrolyzed than esters.

Hydrolysis of procaine >> procainamide

Amide vs. Ester Hydrolysis

No amide hydrolysis

Ester hydrolysis only

Some amides are hydrolyzed at rates comparable to that of esters (maybe because of electronwithdrawing groups).

Hydrolysis of phenacetin produces a toxic amine

Amide Hydrolysis - Enantiomer Toxicity

(

Both enantiomers are anesthetics

NH

2

R )-isomer 

CH

3 causes methemoglobinemia

( S )-isomer not hydrolyzed

Stereospecific metabolism of phensuximide, an anticonvulsant

Enantiomer-Selective Hydrolysis

The ( R )-(-)-ester is hydrolyzed in the liver, but the ( S )-(+)-ester is hydrolyzed in the brain.

Differential Enantiomeric Metabolism

(S)-enantiomer

(R)-enantiomer

SCHEME 8.44

Competitive metabolism of R - and S -etomidate

Phase II Transformations

Conjugation Reactions

Attachment of small polar endogenous molecules to drugs or (more often) to metabolites of phase I enzymes

Further deactivates drugs and produces watersoluble metabolites readily excreted

Conjugation reactions take place with hydroxyl, carboxyl, amino, heterocyclic N , and thiol groups; if not present, a phase I reaction introduces it

Many drugs are excreted without any modification at all.

Mammalian Phase II

Transformations

Table 8.7

Glucuronidation

Biosynthesis and Reactions of UDP-glucuronic Acid

SCHEME 8.45

Biosynthesis and reactions of UDP glucuronic acid

Classes of Compounds Forming Glucuronides

Diseases (inborn errors of metabolism) associated with defective glucuronidation

Crigler-Najjar syndrome and Gilbert’s disease

• deficiency of UDP-glucuronosyltransferase

• adverse effects caused by accumulation of drugs

• inability of neonates to conjugate the antibacterial chloramphenicol ( 8.142

) - “gray baby syndrome”)

Species Specificity, Regioselectivity, and Stereoselectivity

Antibacterial drug sulfadimethoxine is glucuronidated in humans (at arrow) but not in rats, guinea pigs, or rabbits.

OMe

N

H

2

N SO

2

NH N

OMe

Sulfadimethoxine

Two different glucuronides are formed here here

The R,R -(-)-isomer is conjugated with higher affinity, but lower velocity than is the S,S -(+)isomer.

The two hydroxylated isomers of nortriptyline metabolite

8.144

(R = OH) are glucuronidated stereospecifically. Liver and kidney glucuronosyltransferases convert only the E -(+)isomer and the intestinal enzyme converts only the ( E )-(-)isomer.

Human UGTs

• 40-70% of drugs are glucuronidated in humans.

Twenty-two UGTs have been identified.

Polymorphisms of UGT1A1

Polymorphisms of UGT1A3

UGT alleles can lead to severe side effects

Sulfate Conjugation

Occurs less often than glucuronidation (limited availability of SO

4

= ). Main substrates are phenols, but also aliphatic

OH, amines, and thiols (much less).

Glucuronidation and sulfation can occur on the same substrates, but the K m for sulfation is usually lower, so it predominates.

sulfation here

(phenolic OH instead of aliphatic OH) bronchodilator

Hepatotoxicity and Carcinogenicity by Sulfation

SCHEME 8.47

Bioactivation of phenacetin

Amino Acid Conjugation

SCHEME 8.48

Amino acid conjugation

Glycine conjugates are most common in animals.

L -Glutamine conjugates are most common in primates

(insignificant in nonprimates).

Metabolism of Brompheniramine

(antihistamine)

SCHEME 8.49

Metabolism of brompheniramine

Metabolism of diphenhydramine (Benadryl)

The pathway is the same as bromopheniramine, except that it is conjugated with glutamine

Glutathione Conjugation

Glutathione

GSH

Found in all mammalian tissues (5-10 mM in liver and kidneys)

Scavenger of harmful electrophiles

Glutathione

Conjugation

SCHEME 8.50

Examples of glutathione conjugation

Further Metabolism of GSH Conjugates

Metabolism of glutathione conjugates to N -acetyl-

L -cysteine conjugates

Referred to as phase III metabolism

SCHEME 8.51

Metabolism of glutathione conjugates to mercapturic acid conjugates

Water Conjugation

Epoxide hydrolase reactions; such as hydrolysis of arene oxides, as discussed earlier.

Acetyl Conjugation

Important for xenobiotics with primary NH

2

+

Converts ionized amine (RNH

3

) to uncharged amide

O

(RNHCCH

3

)

Metabolites are less water soluble; possibly serves the function of deactivating the drug.

Occurs widely in animals

Extent of N -acetylation in humans is a genetically determined characteristic - called acetylation polymorphism.

• Egyptians are slow acetylators - toxic buildup of drugs but longer drug effectiveness.

• East Asians and Canadian Eskimos are fast acetylators inadequate response.

Acetylation of Amines

SCHEME 8.52

N -Acetylation of amines

Makes less polar:

RNH

3

+ 

Examples of Drugs Exhibiting

Acetylation Polymorphism

Antibacterial

Treatment of leprosy

Antituberculosis

Cilastatin is acetylated. It is administered with Imipenem

Fatty Acid and Cholesterol Conjugation

Fatty acid metabolites of 8.177 and 8.178

deposit in liver, spleen, adipose tissue, and bone marrow.

Cholesterol esters can be formed

Development of the hypolipidemic drug 8.180

had to be stopped because cholesterol esters deposited in the liver.

Methylation - relatively minor in drug metabolism

Generally occurs when the compound has a structural similarity to normal endogenous substrates of the methyltransferase.

SCHEME 8.53

Methylation of xenobiotics

Methylated here regiospecifically bronchodilator

Methylation by catechol O methyltransferase requires a catechol (an aromatic 1,2dihydroxy) substrate. An aromatic

1,3-dihydroxy compound ( 8.185

) does not get methylated.

Phenolic hydroxyls also can get methylated

Methylation here

(minor)

N -Methylation also occurs to a minor extent.

Oxyprenolol is N -dealkylated to 8.187

, R = H, which is methylated to 8.187

, R = CH

3

.

antihypertensive

S -Methylation

Captopril and propylthiouracil are S -methylated.

Reactive metabolites

Atorvastatin and lumiracoxib can form an electrophilic quinone imine.

Hard and Soft Drugs

Sometimes a drug is not metabolized rapidly enough

(long plasma half life). The plasma half life for an analog ( 8.196

) of the antiarthritis drug celecoxib ( 8.195

) in dogs is about a month! To shorten the plasma half life the para -chloro was changed to para -methyl because a carbon next to an aromatic group is known to undergo

P450 oxygenation.

plasma t

1/2

9 h plasma t

1/2

680 h

Compounds (like 8.196

) that are difficult to metabolize are termed hard drugs. Those that are easily metabolized (like 8.195

) are soft drugs

(also called antedrugs).

Soft drugs are designed to have a predictable and controllable metabolism to nontoxic and inactive products after they have achieved their pharmacological effect.

8.197 is a soft analogue of

8.198, an antifungal

Retro Approach Related to Soft Drugs

Identify a biologically inactive metabolite, then modify to an active drug in such a way that this modification is known to be reversed to the inactive metabolite.

The anti-inflammatory agent loteprednol etabonate ( 8.199

) was designed based on the known inactive steroid 8.201

[an analog of the antiinflammatory drug prednisolone ( 8.200

)].

Compound 8.199

is metabolized by esterases to

8.201

after it elicits its antiinflammatory effect.

Download